Madison, WINCT06067503Now EnrollingIRB Ready

Metastatic Cancer Clinical Trial in Madison, WI

Access cutting-edge metastatic cancer treatment through this phase 2 clinical trial at a research site in Madison. Study-provided care at no cost to qualified participants.

Sponsored by University of Wisconsin, Madison

Quick Self-Assessment

See if you qualify for this Madison location

Preparing your pre-screening questions…

Expert Care in Madison

Access metastatic cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic cancer treatment provided free

Apply for This Madison Location

Check if you qualify for this metastatic cancer clinical trial in Madison, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Madison

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Madison site if eligible
  4. 4Begin participation

About This Metastatic Cancer Study in Madison

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.

Sponsor: University of Wisconsin, Madison

Who Can Participate

Inclusion Criteria

Willing to provide informed consent
Individuals at least 18 years of age
Have biopsy-proven ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC) and HER2-negative advanced or metastatic LBC starting new standard of care endocrine therapy
Adequate organ function as indicated by standard laboratory tests (CBC, liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist
Patients with evaluable bone-only disease that is lytic or mixed lytic-sclerotic are eligible
Willing to comply with all study procedures and be available for the duration of the study
Disease may be measurable by RECIST 1.1 criteria or non-measurable. Lesion size must be at least 1cm. If only bone lesions present, they should be lytic or mixed lytic-sclerotic. If only liver lesions present, patient is not eligible.

Exclusion Criteria

Patients with active brain metastases
Patients with liver-only disease are not eligible due to high background liver activity related to the radiopharmaceutical's hepatobiliary route of elimination
Unable to lie flat during or tolerate PET/CT
Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
Presence of liver failure as judged by patient's treating physician
Individuals who are pregnant, lactating, or planning on becoming pregnant during the study
Not suitable for study participation due to other reasons at the discretion of the investigators
Patients with progesterone-receptor negative disease defined as PR \<1 percent by IHC

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Madison?

Yes, this clinical trial (NCT06067503) has an active research site in Madison, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Cancer Treatment Options in Madison, WI

If you're searching for metastatic cancer treatment options in Madison, WI, this clinical trial (NCT06067503) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Madison research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced metastatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic cancer clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Madison, WI

See all advanced solid tumors clinical trials recruiting in Madison — not just this study.

Browse Advanced Solid Tumors Trials in Madison →

Browse More Trials by Condition

Advanced Solid Tumors TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Madison?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Madison, WI